Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss

v3.3.1.900
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Operating expenses        
Research and development $ 609,823 $ 277,359 $ 1,045,493 $ 549,920
Professional and consulting fees 185,572 151,916 446,922 314,937
General and administrative 324,200 183,660 491,948 258,322
Share-based compensation expense (Notes 9(v) and 10) 1,297,558 19,748 1,669,195 90,286
Depreciation (Note 6) 17,002 11,492 27,414 22,691
Total operating expenses 2,434,155 644,175 3,680,972 1,236,156
Other expenses (income)        
Imputed interest expense (Note 7) 0 0 0 30,711
Interest expense 9,963 5,094 10,363 22,269
Other income (25,208) (21,696) (25,295) (502,037)
Change in fair value of warrant derivative liability (Note 11) (917,749) 0 5,469,724 0
Total other expenses (income) (932,994) (16,602) 5,454,792 (449,057)
Net loss for the period (1,501,161) (627,573) (9,135,764) (787,099)
Foreign exchange translation adjustment for the period 0 (3,116) 24,799 (3,098)
Net loss and comprehensive loss for the period $ (1,501,161) $ (630,689) $ (9,110,965) $ (790,197)
Loss per share - basic and diluted (in dollars per share) $ (0.02) $ (0.01) $ (0.16) $ (0.02)
Weighted average number of shares outstanding - basic and diluted (in shares) 68,765,736 46,022,905 57,773,973 41,390,813